Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer

David Onion, Prashant Patel, Robert G. Pineda, Nicholas James, Vivien Mautner

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

We have completed a phase I/II suicide gene therapy clinical trial in patients with prostate cancer, using an E1/E3-deleted replication-deficient adenovirus (CTL102) encoding the bacterial nitroreductase enzyme in combination with prodrug CB1954. This study has provided an opportunity to monitor and characterize vectorand tumor-specific adaptive immunity before and after single or repeat injections of adenovirus. Here we report robust vector-specific humoral and cellular immune responses in all patients monitored. However, we found no correlation between preexisting immunity or the magnitude of the immune response to vector and the clinical outcome as measured by changes in serum prostate-specific antigen (PSA) level. Increased frequency of T cells recognizing prostate-specific antigens PSA or prostate-specific membrane antigen (PSMA) was detected in 3 of 11 patients after therapy, suggesting that this direct cytotoxic strategy can also stimulate tumor-specific immunity.

Original languageEnglish
Pages (from-to)1249-1258
Number of pages10
JournalHuman Gene Therapy
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this